Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗

February 17, 2026

Via Benzinga

Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗

February 17, 2026

FDA approves monthly dosing for J&J's Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.

Via Benzinga

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

Johnson & Johnson (NYSE:JNJ) Stands Out as a High-Quality Dividend Aristocrat for Income Investors ↗

February 07, 2026

Via Chartmill

The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026

February 16, 2026

In a watershed moment for global equity markets, the S&P 500 (INDEXSP:.INX) briefly conquered the psychological 7,000-point milestone in late January 2026, marking the fastest 1,000-point ascent in the...

Via MarketMinute

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Via MarketMinute

Topics Intellectual Property

Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? ↗

February 04, 2026

Via The Motley Fool

Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗

February 14, 2026

On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE: JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc...

Via Benzinga

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

February 13, 2026

From Beasley Allen Law Firm

Via Business Wire

Volatility Returns to Wall Street: VIX Surges 18% as AI Fatigue Triggers Massive Three-Day Sector Rotation

February 13, 2026

The U.S. equity markets faced a grueling three-session losing streak ending Friday, February 13, 2026, as a wave of "AI capex fatigue" and disappointing corporate guidance sent investors scurrying for...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor

February 13, 2026

The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗

February 10, 2026

This reliable dividend payer may be just what the doctor ordered.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property Lawsuit

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

February 09, 2026

From Johnson & Johnson

Via Business Wire

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗

February 09, 2026

Via MarketBeat

Topics ETFs

Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗

February 09, 2026

Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.

Via Benzinga

What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗

February 08, 2026

These companies pay very healthy dividends.

Via The Motley Fool

Topics Bonds

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

February 06, 2026

From Johnson & Johnson

Via Business Wire

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Johnson & Johnson Is A Resilient Blue-Chip Stock And It Just Hit New All-Time Highs ↗

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs.

Via Talk Markets

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from...

Via Barchart.com

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition

February 05, 2026

In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for...

Via MarketMinute

Topics Supply Chain

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

February 02, 2026

From Johnson & Johnson

Via Business Wire

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Via TokenRing AI

Topics Artificial Intelligence

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.